本帖最后由 老马 于 2013-3-13 13:43 编辑 @' `3 z* h1 O2 m7 U3 r; T- j
- z* m8 J/ N& A0 R
健择(吉西他滨)+顺铂+阿瓦斯汀
; v( m9 h. R$ e# i( Q1 l* p Gemzar +Cisplatin + Avastin, g4 {: Y" F; O1 P
http://annonc.oxfordjournals.org/content/21/9/1804.full y. B2 \4 A& c/ }% C3 D
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 8 ~. H" H" i" S5 p3 |( _! m& x
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
" o- ?$ r: \! n- G, IResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
5 e' ]: O# v3 j! J
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 561)
U: o% p, R3 C6 k华为网盘附件:
2 z- d! {+ g( F【华为网盘】ava.JPG
! v0 ]- z# h1 `- p0 S* M |